The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Cardiomyopathy (acute, subacute, chronic)
Publications
Cardiotoxicity following cyclophosphamidetherapy: a case report.
Journal of medical case reports. 2014;8:252
Cyclophosphamide-associated cardiotoxicity in a child after stem cell transplantation for β-thalassemia major: case report and review of the literature.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society. 2014;17(1):50-4
Irreversible end-stage cardiomyopathy following a single dose of cyclophosphamide.
Congestive heart failure (Greenwich, Conn.). 2012;18(4):234-7
Cardiomyopathy following intravenous cyclophosphamide therapy in a patient with Wegener's granulomatosis.
Clinical and experimental rheumatology. 1996;14(6):702-3
Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide.
Cancer research. 1974;34(7):1586-91
Cyclophosphamide-induced cardiomyopathy: a report of two cases and review of the English literature.
Cancer. 1979;43(6):2223-6